Patents by Inventor Pavel Vraspir

Pavel Vraspir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID STATE FORMS OF IXAZOMIB CITRATE
    Publication number: 20210300950
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Application
    Filed: June 14, 2021
    Publication date: September 30, 2021
    Inventors: Martin VALIK, Roman GABRIEL, Pavel VRASPIR, David LUKAS
  • Solid state forms of ixazomib citrate
    Patent number: 11053261
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: July 6, 2021
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Martin Valik, Roman Gabriel, Pavel Vraspir, David Lukas
  • SOLID STATE FORMS OF IXAZOMIB CITRATE
    Publication number: 20200190119
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Inventors: Martin VALIK, Roman GABRIEL, Pavel VRASPIR, David LUKAS
  • Solid state forms of obeticholic acid salts
    Patent number: 10611793
    Abstract: Disclosed are salts of obeticholic acid, solid state forms thereof, processes for preparation thereof, and use thereof in the preparation of pharmaceutical compositions or the preparation of a different solid state form of obeticholic acid or salt thereof, and use in methods of treating liver diseases, e.g. primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: April 7, 2020
    Assignee: TEVA CZECH INDUSTRIES S.R.O.
    Inventors: Pavel Vraspir, Jiri Faustmann
  • Solid state forms of ixazomib citrate
    Patent number: 10604537
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: March 31, 2020
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Martin Valik, Roman Gabriel, Pavel Vraspir, David Lukas
  • SOLID STATE FORMS OF IXAZOMIB CITRATE
    Publication number: 20190330243
    Abstract: The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 31, 2019
    Inventors: Martin VALIK, Roman GABRIEL, Pavel VRASPIR, David LUKAS
  • Solid state forms of cabazitaxel and processes for preparation thereof
    Patent number: 9394266
    Abstract: The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: July 19, 2016
    Assignee: Ivax International GmBh
    Inventors: Pavel Vraspir, Alexandr Jegorov, Roman Gabriel, Ales Gavenda
  • Sunitinib and salts thereof and their polymorphs
    Patent number: 9067915
    Abstract: Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: June 30, 2015
    Assignee: Teva Pharmaceutical Industries LTD.
    Inventors: Alexandr Jegorov, Ales Gavenda, Pavel Vraspir, Augusto Canavesi, Francesca Scarpitta
  • Solid State Forms Of Cabazitaxel And Processes For Preparation Thereof
    Publication number: 20150073159
    Abstract: The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 12, 2015
    Inventors: Ondrej SIMO, Pavel VRASPIR, Tomas HOLAS, Alexandr JEGOROV, Roman GABRIEL
  • SOLID STATE FORMS OF CABAZITAXEL AND PROCESSES FOR PREPARATION THEREOF
    Publication number: 20150038564
    Abstract: The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.
    Type: Application
    Filed: March 7, 2013
    Publication date: February 5, 2015
    Inventors: Pavel Vraspir, Alexandr Jegorov, Roman Gabriel, Ales Gavenda
  • Solid state forms of cabazitaxel and processes for preparation thereof
    Patent number: 8921411
    Abstract: The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel. The present invention further provides pharmaceutical compositions comprising one or more of the solid state forms of Cabazitaxel, and a method of treating hormone-refractory prostate cancer.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: December 30, 2014
    Assignee: Plus Chemicals SA
    Inventors: Ondrej Simo, Pavel Vraspir, Tomas Holas, Alexandr Jegorov, Roman Gabriel
  • SOLID STATE FORMS OF CABAZITAXEL AND PROCESSES FOR PREPARATION THEREOF
    Publication number: 20140011865
    Abstract: The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel. The present invention further provides pharmaceutical compositions comprising one or more of the solid state forms of Cabazitaxel, and a method of treating hormone-refractory prostate cancer.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 9, 2014
    Applicant: PLUS CHEMICALS SA
    Inventors: Ondrej SIMO, Pavel Vraspir, Tomas Holas, Alexandr Jegorov, Roman Gabriel
  • Sunitinib and salts thereof and their polymorphs
    Patent number: 8618309
    Abstract: Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: December 31, 2013
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Alexandr Jegorov, Ales Gavenda, Pavel Vraspir, Augusto Canavesi, Francesca Scarpitta
  • SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS
    Publication number: 20130296575
    Abstract: Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 7, 2013
    Inventors: Alexandr JEGOROV, Ales Gavenda, Pavel Vraspir, Augusto Canavesi, Francesca Scarpitta
  • Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof
    Patent number: 8067423
    Abstract: The invention provides crystalline forms of isopropyl alcohol solvate of dasatinib, methods for their preparation, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: November 29, 2011
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Ondrej {hacek over (S)}imo, Ji{hacek over (r)}í Filip{hacek over (c)}ík, Alexandr Martaus, Alexandr Jegorov, Ale{hacek over (s)} Gavenda, Judith Aronhime, Pavel Vraspir, Tamás Koltai, Ji{hacek over (r)}í Faustmann, Roman Gabriel
  • Anhydrous form of dasatinib and process for preparation thereof
    Patent number: 7973045
    Abstract: The invention provides anhydrous forms of dasatinib, methods for their preparation, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: July 5, 2011
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Ondrej {hacek over (S)}imo, Ji{hacek over (r)}í Filip{hacek over (c)}ík, Alexandr Martaus, Alexandr Jegorov, Ale{hacek over (s)} Gavenda, Judith Aronhime, Pavel Vraspír, Tamás Koltai, Ji{hacek over (r)}í Faustmann, Roman Gabriel
  • SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS
    Publication number: 20110118477
    Abstract: Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate.
    Type: Application
    Filed: July 23, 2009
    Publication date: May 19, 2011
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Alexandr Jegorov, Ales Gavenda, Pavel Vraspir, Augusto Canavesi, Francesca Scarpitta
  • POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20100256158
    Abstract: Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 14, 2010
    Publication date: October 7, 2010
    Inventors: Ondrej SIMO, Jirí Filipcik, Alexandr Martaus, Alexandr Jegorov, Ales Gavenda, Judith Aronhime, Pavel Vraspír, Tamás Koltai, Jirí Faustmann, Roman Gabriel
  • POLYMORPHS OF SUNITINIB BASE AND PROCESSES FOR PREPARATION THEREOF
    Publication number: 20100256392
    Abstract: The present invention provides polymorphs of Sunitinib base and processes for preparation thereof.
    Type: Application
    Filed: November 21, 2008
    Publication date: October 7, 2010
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Ales Gavenda, Ettore Bigatti, Alexandr Jegorov, Augusto Canavesi, Pavel Vraspir, Judith Aronhime, Peter Lindsay MacDonald, Francesca Scarpitta, Marco Villa, Paolo Angioletti
  • CRYSTALLINE FORMS OF ERLOTINIB BASE AND ERLOTINIB HCL
    Publication number: 20100004449
    Abstract: The preparation of crystalline Erlotinib base form G2 is described. This crystalline form can be converted to an Erlotinib salt, such as Erlotinib HCl, which can be used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: July 7, 2009
    Publication date: January 7, 2010
    Applicant: PLUS CHEMICALS SA
    Inventors: Ales GAVENDA, Pavel VRASPIR, Augusto CANAVESI, Judith ARONHIME, Ettore BIGATTI, Jiri FAUSTMANN, Alexandr JEGOROV, Peter W. STEPHENS, Giovanna LUX, Maurizio PAIOCCHI